Bibliography
- Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002;159:469-73
- Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
- Wade AG, Lemming O, Hedegaard KB. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002;17:95-102
- Lepola UM, Loft H, Reines EH. Escitalopram (10 – 20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol2003;18:211-17
- Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalised anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006;9:495-505
- Baldwin DS, Huusom AKT, Mæhlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry2006;189:264-72
- Fineberg NA, Lemming O, Tonnoir B, Stein DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 2007;17:430-9
- Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003;64:1322-7
- Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70
- Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM)76-338. Rockville, MD: National Institute of Mental Health; 1976:218-22
- de Waard F. Body mass index. J Chronic Dis 1978;31:129
- Zung Wwk, Magruder-Habib K, Velez R, et al. The comorbidity of anxiety and depression in general medical patients: a longitudinal study. J Clin Psychiatry 1990;51(Suppl 6):77-80
- Zimbroff Dl, Bose A, Li D. Escitalopram treatment of SSRI non-responders can lead to remission in patients who fail initial SSRI therapy. Poster Presented at the 56th Annual American Psychiatric Association Institute on Psychiatric Services; 2004 October 6 – 10; Atlanta, GA, USA
- Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anx 2005;21:26-32
- Prapotnik M, Di Pauli J, Vetter Z, et al. Antidepressant-associated mania with escitalopram. Eur Psychiatry 2004;19:455-6
- Bobo WV, Grammer GG. Escitalopram-associated mania. Mil Med 2003;168:ii
- Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
- Kennedy SH, Andersen HF, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31